News and Announcements
Innovative New Rapid Blood Test to Tackle Tropical Diseases from Atomo Diagnostics
- Published May 31, 2016 1:43PM UTC
- Publisher Wholesale Investor
- Categories Company Updates
30th May 2016, Atomo Diagnostics
Award-winning designer and manufacturer of diagnostic medical devices, Atomo Diagnostics today announced that it has been successful in securing $1.38 million in grant funding from the Australian Government to assist in the development and commercialisation of new rapid tests for the detection of dengue and chikungunya viruses.
Half the world’s population live in areas at risk of infection from these two viruses, which are leading causes of illness and death in the tropics and subtropics . Readily transmitted by mosquitoes, there are no vaccines to prevent infection so early detection and treatment is critical to limit the risk of complications and death.
Atomo’s Group CEO John Kelly said, “We are extremely grateful to the Australian government for its commitment to global health innovation and continued support of our company. This funding will help us deliver a much needed, easy-to-use solution for the rapid diagnosis of diseases which impact hundreds of millions of people.”
Atomo’s all-in-one integrated rapid diagnostic tests (RDTs) are recognised internationally for their excellent usability and performance. The company’s first product to market, AtomoRapid HIV, was awarded ‘Best in Show’ at the prestigious Medical Design Excellence Awards in New York in 2014.
To view the full article, please click on the button below.